CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 254 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,871,914 | -17.0% | 416,759 | -4.6% | 0.00% | 0.0% |
| Q2 2023 | $5,872,851 | -22.2% | 436,968 | -4.0% | 0.00% | 0.0% |
| Q1 2023 | $7,547,862 | -36.3% | 455,239 | -28.5% | 0.00% | -50.0% |
| Q4 2022 | $11,846,000 | +48.4% | 636,741 | +2.3% | 0.00% | +33.3% |
| Q3 2022 | $7,985,000 | +446.9% | 622,355 | +198.7% | 0.00% | +200.0% |
| Q2 2022 | $1,460,000 | -10.6% | 208,321 | +5.7% | 0.00% | – |
| Q1 2022 | $1,633,000 | -55.2% | 197,080 | -63.4% | 0.00% | -100.0% |
| Q4 2021 | $3,647,000 | +1025.6% | 538,859 | +783.0% | 0.00% | – |
| Q3 2021 | $324,000 | +548.0% | 61,027 | +457.1% | 0.00% | – |
| Q1 2021 | $50,000 | +35.1% | 10,955 | 0.0% | 0.00% | – |
| Q4 2020 | $37,000 | -57.0% | 10,955 | -62.0% | 0.00% | – |
| Q3 2020 | $86,000 | -30.6% | 28,866 | +7.7% | 0.00% | – |
| Q2 2020 | $124,000 | -90.7% | 26,792 | -92.2% | 0.00% | -100.0% |
| Q4 2017 | $1,337,000 | – | 341,956 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |